- Home
- CATY vs KNSA Comparison
CATY vs KNSA Comparison
Compare CATY & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CATY | KNSA |
|---|---|---|
| Founded | 1962 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.5B |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CATY | KNSA |
|---|---|---|
| Price | $53.52 | $47.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $52.75 | ★ $55.29 |
| AVG Volume (30 Days) | 387.0K | ★ 565.9K |
| Earning Date | 04-22-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.82% | N/A |
| EPS Growth | 14.94 | ★ 225.00 |
| EPS | ★ 4.54 | 0.75 |
| Revenue | $53,793,000.00 | ★ $677,564,000.00 |
| Revenue This Year | $20.37 | $38.01 |
| Revenue Next Year | $5.41 | $17.42 |
| P/E Ratio | ★ $11.87 | $63.27 |
| Revenue Growth | 2.93 | ★ 60.09 |
| 52 Week Low | $36.66 | $19.42 |
| 52 Week High | $54.99 | $50.03 |
Technical Indicators
Market Signals| Indicator | CATY | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 70.96 | 51.17 |
| Support Level | $46.90 | $39.96 |
| Resistance Level | $54.90 | $48.14 |
| Average True Range (ATR) | 1.02 | 1.83 |
| MACD | 0.63 | -0.03 |
| Stochastic Oscillator | 89.06 | 45.20 |
Price Performance
Historical ComparisonAbout CATY Cathay General Bancorp
Cathay General Bancorp is a regional bank predominantly serving the Chinese-American community. The company's policy is to reach out and actively offer services to low-to-moderate income groups in the delineated branch service areas. It predominantly provides services such as checking and deposit, lines of credits, commercial and commercial real estate loans, merchant services and payment processing, treasury management services, international banking and financing services, and other customary banking services to individuals, professionals, and small to medium-sized businesses. Through its Wealth Management unit, the company also offers investment products and services, such as stocks, bonds, mutual funds, insurance, annuities and advisory services.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.